Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Here’s Why

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $22.13, but opened at $23.50. Nanobiotix shares last traded at $23.4940, with a volume of 1,292 shares traded.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. Leerink Partners restated an “outperform” rating on shares of Nanobiotix in a report on Tuesday, November 25th. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $11.00.

Nanobiotix Stock Up 3.8%

The firm’s 50-day moving average price is $21.35 and its 200 day moving average price is $13.51.

Institutional Trading of Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Optiver Holding B.V. bought a new stake in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,356 shares of the company’s stock, valued at approximately $101,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.